# A Study of HDM2020 in Patients With Advanced Sq-NSCLC

> **NCT07638891** · PHASE1 · RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Squamous Non-small Cell Lung Cancer(NSCLC)

## Interventions

- **DRUG:** HDM2020 (FGFR2b-ADC)

## Key facts

- **NCT ID:** NCT07638891
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-11-03
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07638891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07638891, "A Study of HDM2020 in Patients With Advanced Sq-NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07638891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*